Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.

@article{Kumada2016VaniprevirPP,
  title={Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.},
  author={Hiromitsu Kumada and Satoshi Mochida and Fumitaka Suzuki and Kazuaki Chayama and Yoshiyasu Karino and Keisuke Nakamura and Go Fujimoto and Anita Yee Mei Howe and Steve W. Ludmerer and Niloufar Mobashery},
  journal={Journal of gastroenterology and hepatology},
  year={2016},
  volume={31 10},
  pages={1674-1683}
}
BACKGROUND AND AIM Vaniprevir is a macrocyclic hepatitis C virus (HCV) non-structural (NS)3/4A protease inhibitor. The objective of these phase 3 multicenter, open-label trials was to evaluate the safety and efficacy of vaniprevir + peginterferon alfa-2b + ribavirin (PR) in Japanese patients with HCV genotype (GT)1 infection who had previously failed treatment with interferon-based regimens. METHODS Japanese patients with chronic HCV GT1 were enrolled. In PN044, patients with previous relapse… CONTINUE READING